How to Explore GLP-1-Based Care for Weight-Related Goals

What Is Semaglutide and How Might It Support Weight Management?

Semaglutide is a type of GLP-1 receptor agonist, a class of medications used under medical supervision for managing certain health conditions. One FDA-approved form of semaglutide, marketed as Wegovy®, is approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition.

In clinical trials, including the STEP 1 study, adults with obesity or overweight who were prescribed semaglutide (Wegovy®) alongside dietary and lifestyle support experienced an average weight reduction of up to 14.9% over 68 weeks.

Note: This data applies specifically to the FDA-approved medication Wegovy® and may not reflect results from other versions or uses of semaglutide. Always consult a licensed provider to determine whether a GLP-1-based treatment is appropriate for your individual health needs.

‍

Who Might Be Eligible for GLP-1-Based Treatment?

Prescription medications in the GLP-1 class, such as semaglutide, must be evaluated and prescribed by a licensed healthcare provider. Eligibility is determined based on clinical guidelines and an individual’s overall health profile.

A provider may consider GLP-1 treatment for adults who meet one of the following criteria:

• A body mass index (BMI) of 30 or higher, or
• A BMI of 27 or higher with at least one weight-related condition, such as high blood pressure, elevated cholesterol, or type 2 diabetes

In addition to BMI, providers typically assess the following during the consultation:

• Personal and family medical history, including thyroid disease or pancreatitis
• Current medications and potential interactions
• Lab work, such as glucose levels and kidney or liver function

Treatment decisions are made on a case-by-case basis by the prescribing provider. Eden’s role is to help you connect with licensed clinicians who can guide you through the process when eligible.

‍

How to Get Started with GLP-1-Based Care: A Step-by-Step Overview

Access to GLP-1 medications like semaglutide begins with a clinical evaluation by a licensed provider. Eden offers a telehealth platform that connects patients with qualified medical professionals who can assess eligibility and discuss treatment options based on individual needs.

Step 1: Connect with a LIcensed Provider

Schedule a virtual consultation through Eden’s secure telehealth platform. During this visit, a licensed clinician will learn more about your health goals and determine whether GLP-1-based care may be appropriate.

Step 2: Complete a Medical Intake

Share your medical history, current medications, and lifestyle habits through a secure intake process. Your provider may also request lab work to help determine whether treatment is appropriate.

Step 3: Provider Determines Eligibility

Based on your health information and clinical guidelines, the provider will determine if a prescription is appropriate. If eligible, your provider may discuss options that include FDA-approved GLP-1 medications.

Step 4: Begin a Personalized Plan 

If prescribed, your treatment plan may include a gradual dose schedule designed to support tolerability and safety. Your provider will give clear instructions on how to begin and adjust as needed.

Step 5: Ongoing Monitoring and Support

Follow-up visits are an important part of care. Providers may check in regularly to assess your progress, adjust your treatment plan, and offer support with lifestyle changes that complement your medical care.

‍

Online vs. In-Person Access: What’s the Difference?

Whether you're exploring care in person or through a telehealth platform, licensed medical providers are the only professionals who can evaluate your eligibility for GLP-1 medications like semaglutide.

In-Person Care

Visiting a clinic or healthcare office may provide immediate access to physical exams and on-site lab testing. Some patients prefer the familiarity and face-to-face interaction of traditional care settings.

Telehealth Access through Eden

Eden offers a digital platform that connects you with licensed healthcare providers from the comfort of your home. Through secure virtual visits, providers can evaluate your medical history, order lab work when needed, and determine whether treatment—including GLP-1 medications—is clinically appropriate.

Note: All prescribing decisions are made solely by independent, licensed providers. Eden does not practice medicine or dispense medications.

‍

Cost and Insurance Considerations

The out-of-pocket cost of GLP-1 medications, such as semaglutide, can vary significantly depending on the brand, insurance coverage, and pharmacy pricing. Approved options like Wegovy® and Ozempic® may retail for $800–$950 per month without insurance.

Ways to Reduce Costs

Depending on your provider’s recommendation and your individual insurance plan, you may have access to:

• Insurance coverage for FDA-approved GLP-1 medications
• Manufacturer savings programs or co-pay cards
• Pharmacy discount cards or programs offered by select retail pharmacies

Your provider can help you understand which medications may be clinically appropriate and guide you on navigating coverage or affordability options.

Note: Eden does not prescribe or dispense medication. If treatment is prescribed, medications are filled by licensed third-party pharmacies.

‍

Final Thoughts

Exploring GLP-1 medications like semaglutide for weight-related goals starts with connecting to the right medical provider. Whether you're just beginning your research or ready to take the next step, Eden offers a trusted telehealth platform that helps you connect with licensed clinicians for personalized, judgment-free care.

If appropriate, a provider may prescribe FDA-approved GLP-1 medications as part of a comprehensive treatment plan that supports your long-term health goals.

Eden does not practice medicine or dispense medications. Eden’s role is to connect individuals with independent, licensed providers. If a provider determines that treatment is appropriate, medications are filled by state-licensed third-party pharmacies.

‍

Disclaimers

This content is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Any decision to begin a prescription medication must be made by a licensed healthcare provider based on an individual’s unique health profile.

Semaglutide is approved by the U.S. Food and Drug Administration (FDA) under the brand name Ozempic® for the treatment of type 2 diabetes and under the brand name Wegovy® for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition.

All prescribing decisions are made solely by licensed medical providers. Treatment plans are based on clinical guidelines, medical history, and a provider’s professional judgment.

‍